Cannabidivarin (CBDV, GWP42006) is a non-intoxicating psychoactive cannabinoid found in Cannabis. It is a homolog (chemistry) of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. CBDV demonstrated anticonvulsant in rodent models in a single published study. It was identified for the first time in 1969 by Vollner et al. Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see: Cannabidiol). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006) because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action. GW has begun several Phase-2 trials for adult epilepsy, for childhood epilepsy and for Prader-Willi Syndrome.